Diabetes drug proving efficient, according to Novartis

According to pharmaceutical company Novartis AG, the diabetes drug Galvus is proving to be both efficient and well-tolerated by type 2 diabetics currently undergoing a clinical trial.
The study, comprising 544 patients suffering from type 2 diabetes, was given standard metformin treatment alongside diabetes drug Galvus. A contrast group were given metformin with a placebo. Four times as many patients in the galvus trial achieved recommended blood sugar control levels .
Novartis also examined a subset group, who reported an even more impressive correlation between galvus use and achieving glycaemic control. Galvus is expected to become a blockbuster drug for the medical company.